Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Brian P. Monahan, MD, FACP
National Cancer Institute (NCI)
- Eva Szabo, MD
National Cancer Institute (NCI)
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Center for Cancer Research
Bethesda, Maryland, United States
- Warren Grant Magnuson Clinical Center - Nci Clinical Studies Support
Bethesda, Maryland, United States
- Naval Medical Center, Portsmouth
Portsmouth, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2001
- Primary completion
- —
- Completion
- 30 Jun 2004
- Last update posted
- 8 Mar 2012
- Registered enrollment
- —
- Registry id
- NCT00021047
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.